Loading...
XSHE300289
Market cap348mUSD
Jan 06, Last price  
4.69CNY
1D
0.43%
1Q
-17.43%
Jan 2017
-62.33%
IPO
-24.84%
Name

Beijing Leadman Biochemistry Co Ltd

Chart & Performance

D1W1MN
XSHE:300289 chart
P/E
166.35
P/S
5.53
EPS
0.03
Div Yield, %
0.01%
Shrs. gr., 5y
3.95%
Rev. gr., 5y
-6.76%
Revenues
462m
-34.62%
103,809,747143,265,563185,624,994252,083,942317,273,827343,630,223536,970,837681,675,798533,391,826575,978,026654,804,224515,143,483471,510,962564,057,983705,976,839461,554,624
Net income
15m
26,162,27841,414,91154,398,70271,850,81998,287,089110,072,010128,281,332157,219,57169,648,57173,067,13540,471,7246,309,184022,419,197015,337,378
CFO
134m
+23.40%
21,982,23831,262,53453,464,38829,344,91857,855,64190,446,0140177,817,69181,775,815120,965,20681,020,993124,648,403135,559,303119,058,284108,933,825134,420,515
Dividend
May 17, 20240.01 CNY/sh
Earnings
Apr 29, 2025

Profile

Beijing Leadman Biochemistry Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products in the People's Republic of China. The company offers biochemical raw materials, such as enzymes, coenzymes, antibodies, buffers, enzyme substrates, culture media, stain reagents, amino acids, and other products primarily for biotechnology, clinical diagnosis, drug development, chemical production, and other related applications. It also provides biochemistry diagnostic and companion reagents. In addition, the company offers medical instruments, such as EnigmaML, an automated molecular test platform for use in clinical laboratory and at the point-of-care, including clinics, doctor's surgeries, and pharmacies; DiaSys InnovaStar, an automatic compact POCT analyzer to deliver result quality comparable to measurements on laboratory analyzers; DiaSys Respons, a random access bench top analyzer; CI1000 automatic chemiluminescence immunoassay analyzers; and IDS-isys, an instrument to enhance performance and productivity. The company was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
URL
http://www.leadmanbio.com
IPO date
Feb 16, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
461,555
-34.62%
705,977
25.16%
Cost of revenue
330,041
579,706
Unusual Expense (Income)
NOPBT
131,514
126,271
NOPBT Margin
28.49%
17.89%
Operating Taxes
1,871
10,870
Tax Rate
1.42%
8.61%
NOPAT
129,643
115,401
Net income
15,337
 
Dividends
(201)
(10,877)
Dividend yield
0.01%
0.35%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
51,015
Long-term debt
9,305
16,233
Deferred revenue
18,319
Other long-term liabilities
16,287
33,194
Net debt
(1,011,506)
(925,305)
Cash flow
Cash from operating activities
134,421
108,934
CAPEX
(18,689)
Cash from investing activities
(355,457)
Cash from financing activities
(12,258)
FCF
224,185
162,762
Balance
Cash
855,315
798,810
Long term investments
165,495
193,742
Excess cash
997,733
957,253
Stockholders' equity
1,118,935
1,169,655
Invested Capital
827,836
917,676
ROIC
14.85%
11.20%
ROCE
7.18%
6.72%
EV
Common stock shares outstanding
511,246
544,011
Price
6.15
6.77%
5.76
-28.62%
Market cap
3,144,163
0.34%
3,133,506
-13.40%
EV
2,194,644
2,261,364
EBITDA
193,204
189,179
EV/EBITDA
11.36
11.95
Interest
737
1,289
Interest/NOPBT
0.56%
1.02%